family with sequence similarity 174 member AGenealiases: HGS_RE408 · NS5ATP6 · TMEM157 · UNQ1912
Q-omics provides the consensus-scored FAM174A profile across patient tissues and cancer cell-line models. FAM174A expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, FAM174A is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, FAM174A RNA expression shows 18,788 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, and UVM as cancer lineages where FAM174A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM174A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM174A survival associations across molecular data types. FAM174A RNA expression shows survival associations in the most cancer types (27), followed by mutation status (4) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM174A RNA expression–survival associations across cancer types. High FAM174A expression shows unfavorable associations in HNSC, UVM, STAD and CESC, but favorable associations in KIRC and SKCM. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for FAM174A RNA expression.
This table summarizes FAM174A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for FAM174A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM174A shows lower tumor expression in LUSC, LUAD and COAD and higher tumor expression in KIRC, LIHC and BRCA. The KIRC box plot shows higher FAM174A RNA expression in tumor versus normal tissue (log2 FC = +0.772, t-test p < 0.001).
This table shows molecular features associated with FAM174A in patient tissues and cancer cell lines. In patient samples, FAM174A shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, FAM174A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in BONE and BREAST.
